October 21st, 2020
New approaches to developing career-related learning for primary school children and an app to boost interaction between those living with dementia and their carers have been included in a list of top innovations.
The Australian Financial Review’s BOSS Most Innovative Companies survey split’s Australian and New Zealand industry into separate categories. Innovative programs provided by the Smith Family and Dementia Australia are included in the Top Ten of the government, education and Not-for-Profit Category.
The Smith Family’s Future Seekers program is designed to engage primary school students in grades four to six in an interactive approach to exploring how their interests can apply to the world of work. Its goal is to help boost students’ self-belief and to consider different career aspirations that can help their engagement with school. Schools and students were involved in the program’s preliminary consultations. It has already been rolled out to more than 500 students from low socio-economic areas and is planned to grow.
Dementia Australia’s A Better Visit initiative is a free app that aims to increase interaction between those living with dementia and their families and friends. The app includes two-player games with images and sounds to enhance enjoyment and stimulate interaction between carers and those living with dementia. It has already been downloaded more than 5000 times.
The app is a collaboration between Dementia Australia, Lifeview Residential Care and Swinburne University of Technology’s Future Self and Design Living Lab. The games are a result of a co-creative process between people living with moderate and advanced dementia and their visitors.
The WWF program Impactio, which was featured recently in Philanthropy Weekly, was also included on the list.
Do you want to know who is funding what and where across Australia?
Access the Australian Communities Foundation National Funding Portal for philanthropic funders to connect with the funding opportunities available to tackle COVID-19.